Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Novartis Zelnorm patient information (correction)

Executive Summary

Novartis has agreed to assess the distribution of patient prescribing information as a Phase IV commitment required for approval of its chronic constipation indication. "The Pink Sheet" had incorrectly reported that the company would assess the distribution of Zelnorm "Medguides" (1"The Pink Sheet" Aug. 30, 2004, p. 8). Zelnorm is not required to be distributed with a Medguide...

You may also be interested in...

Novartis To Assess Zelnorm “Medguide” Distribution In Phase IV Study

Novartis will create a protocol to assess the distribution of the Zelnorm "Medguide" to patients as one Phase IV commitment following FDA approval of a chronic idiopathic constipation indication

Flying High: Quest Teams With Las Vegas Walmart To Deliver COVID-19 Tests By Drone

Look! Up in the sky! It’s a bird! It’s a plane! It’s … a COVID-19 test from Quest Diagnostics.

Executives On The Move: New CEO Appointed At Xwpharma

New directors at 4D Pharma, Neurogene And Zogenix.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts